TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36585127

Group type: EXPERIMENTAL
Intervention: Abatacept 125 mg/mL weekly subcutaneous injections
Number of subjects: 15
Study: 36585130

Group type: EXPERIMENTAL
Intervention: Enalapril (starting at 2.5 mg two times per day, titrating up to a maximum dose of 10 mg two times per day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care (high-dose anthracycline-based chemotherapy)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 106
Study: 36585131

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 870

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study: 36585135

Group type: EXPERIMENTAL
Intervention: Self-hypnosis training for 10 minutes/day over 8 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-hypnosis training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60
Study: 36585137

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine
Number of subjects: 6943
Study: 36585139

Group type: EXPERIMENTAL
Intervention: Daily synbiotic intervention (combining human milk oligosaccharide and probiotic)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Identical-looking placebo
Number of subjects: 144
Study: 36585141

Group type: EXPERIMENTAL
Intervention: Sleep measurements and CSF-orexin-A
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Changes in AD and/or glial activation markers
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 200
Study: 36585144

Group type: EXPERIMENTAL
Intervention: Mobile phone-based telemonitoring programme
Number of subjects: 50
Study: 36585147

Group type: EXPERIMENTAL
Intervention: IYCF intervention (behaviour change modules and small-quantity lipid-based nutrient supplements from 6 to 12 months of age)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: IYCF-plus intervention (IYCF components plus powdered NUA-45 biofortified sugar beans, whole egg powder, moringa leaf powder, and provitamin A maize)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: IYCF-plus intervention
Number of subjects: 192
Study: 36585153

Group type: EXPERIMENTAL
Intervention: Prophylactic mesh placement during index operation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Questionnaires developed using a 5-point Likert scale
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Semistructured interviews
Number of subjects: 120
Study: 36585217

Group type: EXPERIMENTAL
Intervention: Abatacept + MTX
Number of subjects: 752

Group type: COMPARATOR
Intervention: Abatacept placebo + MTX
Number of subjects: 752
Study: 36585408

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.1 mg/day) plus oral micronized progesterone (200 mg/day as 100 mg twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Matched placebo (PBO)
Number of subjects: 28
Study: 36585452

Group type: EXPERIMENTAL
Intervention: Ricolinostat plus nab-paclitaxel
Number of subjects: 3000
Study: 36585491

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (ET)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (ET) and Placebo (PLC)
Number of subjects: 31
Study: 36585494

Group type: EXPERIMENTAL
Intervention: RYGB + Exercise Training (RYGB + ET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 30
Study: 36585602

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-17 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eDaily by PsABIOnd substudy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wearable and digital technologies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety data collection
Number of subjects: 0
Study: 36585608

Group type: EXPERIMENTAL
Intervention: Osmotherapy
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Age ≥ 77 years
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score ≤ 9
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Injury Severity Score (ISS) ≥ 25
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Overall GOSE score at 3 months
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Mortality rate at 3 months
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Withdrawal or withholding of life-sustaining therapies
Number of subjects: 349
Study: 36585629

Group type: COMPARATOR
Intervention: Postoperative Stereotactic Radiosurgery (SRS)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic Radiosurgery (SRS)
Number of subjects: 88
Study: 36585664

Group type: EXPERIMENTAL
Intervention: Nanosilver fluoride (NSF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 50
Study: 36585676

Group type: EXPERIMENTAL
Intervention: Gait Enhancing and Motivating System for Hip (exoskeleton) used in twelve 30-min sessions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional exercise programs
Number of subjects: 12
Study: 36585673

Group type: EXPERIMENTAL
Intervention: Institutional delivery
Number of subjects: 4423

Group type: COMPARATOR
Intervention: Non-institutional delivery
Number of subjects: 4423
Study: 36585700

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) from ICI responding donor
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fecal microbiota transplantation (FMT) from ICI nonresponding donor
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 24
Study: 36585748

Group type: EXPERIMENTAL
Intervention: 12-week telehealth exercise program based on the Mann Method
Number of subjects: 18
Study: 36585933

Group type: EXPERIMENTAL
Intervention: Internet-based exposure therapy for fibromyalgia (10 weeks)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 140
Study: 36585956

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-diabetic control group
Number of subjects: 17
Study: 36586038

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1709

Group type: COMPARATOR
Intervention: Public healthcare system
Number of subjects: 1709

Group type: COMPARATOR
Intervention: Private healthcare system
Number of subjects: 1709
Study: 36586101

Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No Ribavirin (Control)
Number of subjects: 8
Study: 36586213

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 278
Study: 36586351

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate treatment (DMF)
Number of subjects: 42
Study: 36586514

Group type: EXPERIMENTAL
Intervention: 30-mg oral melatonin
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 36586583

Group type: EXPERIMENTAL
Intervention: 0.5%, 0.75%, or 1.5% ruxolitinib cream applied twice daily for 28 days
Number of subjects: 71
Study: 36586812

Group type: EXPERIMENTAL
Intervention: Sleep duration ≥9 hours
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Sleep duration 7 to <8 hours
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Later sleep midpoints (3rd tertile)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Later sleep midpoints (2nd tertile)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Social jetlag (continuous per hour)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Night shift work
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Non-night shift work
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Sleep duration ≥9 hours (excluding shift workers)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Preconception sleep
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1228
Study: 36587174

Group type: EXPERIMENTAL
Intervention: Theranostic-guided riboflavin/UV-A corneal cross-linking (CXL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epithelium-off or epithelium-on CXL
Number of subjects: 50
Study: 36587281

Group type: EXPERIMENTAL
Intervention: Individualized nutrition support
Number of subjects: 517

Group type: COMPARATOR
Intervention: Usual-care nutrition
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Low prealbumin levels
Number of subjects: 517
Study: 36587393

Group type: EXPERIMENTAL
Intervention: nsPEF ablation
Number of subjects: 15
Study: 36587547

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine supplemented analgesia
Number of subjects: 118
Study: 36587801

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with osteoporosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with osteopenia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postmenopausal women with normal BMD
Number of subjects: 100

Group type: COMPARATOR
Intervention: Premenopausal women with normal BMD
Number of subjects: 100
Study: 36587890

Group type: EXPERIMENTAL
Intervention: Subcutaneous C.E.R.A. administration every 4 weeks
Number of subjects: 40
Study: 36588113

Group type: EXPERIMENTAL
Intervention: PBM treatment (590, 660 and 850 nm) 3 times per week over 3-4 weeks (9 treatments per series)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PBM treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: PBM treatment and sham treatment
Number of subjects: 44
Study: 36588137

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Risankizumab 300 mg
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 36588166

Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 911

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911
Study: 36588335

Group type: EXPERIMENTAL
Intervention: Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD-27)
Number of subjects: 0
Study: 36588387

Group type: EXPERIMENTAL
Intervention: Idarubicin plus busulfan and cyclophosphamide (IDA-BuCy)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Busulfan and cyclophosphamide (BuCy)
Number of subjects: 154
Study: 36588397

Group type: EXPERIMENTAL
Intervention: Medical therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comorbid conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional performance
Number of subjects: 0
Study: 36588672

Group type: EXPERIMENTAL
Intervention: Yupingfeng Powder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36588741

Group type: EXPERIMENTAL
Intervention: Ganshuang granule combined with tenofovir; dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details not available
Number of subjects: 0
Study: 36588884

Group type: EXPERIMENTAL
Intervention: Neurohawk retriever
Number of subjects: 232

Group type: COMPARATOR
Intervention: Solitaire FR
Number of subjects: 232
Study: 36589413

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) data analysis
Number of subjects: 211
Study: 36589545

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training program (supervised progressive resistance and strength exercise over 3 consecutive days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36589629

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 16
Study: 36589863

Group type: EXPERIMENTAL
Intervention: Multiple sets resistance training plus aerobic training
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Single set resistance training plus aerobic training
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 36589958

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 condition (long COVID)
Number of subjects: 61655

Group type: EXPERIMENTAL
Intervention: PCR positive test group
Number of subjects: 61655

Group type: COMPARATOR
Intervention: PCR negative test group
Number of subjects: 61655
Study: 36590610

Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study: 36590621

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Intensity Continuous Training (MVCT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study: 36590787

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg over 40 min)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 394
Study: 36590789

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) once daily for 10 days
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 36591351

Group type: EXPERIMENTAL
Intervention: Automated segmentation model for kidney and liver in MRI scans
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Automated TKV measurement
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Automated TLV estimation
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Automated TKV for external dataset
Number of subjects: 327
Study: 36591610

Group type: EXPERIMENTAL
Intervention: Optimised treatments
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Quadruple therapy containing metronidazole, tetracycline and bismuth
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Triple amoxicillin-levofloxacin therapy
Number of subjects: 2144

Group type: COMPARATOR
Intervention: Overall treatments
Number of subjects: 2144

Group type: COMPARATOR
Intervention: Overall incidence of adverse events
Number of subjects: 2144
Study: 36591612

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 883

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 883
Study: 36591636

Group type: EXPERIMENTAL
Intervention: Videoconferencing acceptance and commitment therapy (ACT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (psychoeducation materials only)
Number of subjects: 19
Study: 36591795

Group type: EXPERIMENTAL
Intervention: Polysomnography-derived respiratory indices during inpatient acute rehabilitation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chronic pain status assessment at 1- to 2-year follow-up
Number of subjects: 66
Study: 36591808

Group type: EXPERIMENTAL
Intervention: Preoperative transvaginal ultrasonography
Number of subjects: 1079
Study: 36592299

Group type: EXPERIMENTAL
Intervention: High-dose cephalexin (1000 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard-dose cephalexin (500 mg)
Number of subjects: 33
Study: 36592498

Group type: EXPERIMENTAL
Intervention: PLCOm2012 risk model
Number of subjects: 0
Study: 36592505

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid 6-monthly (≤6 infusions, n=170)
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid 6-monthly (≥7 infusions, n=555)
Number of subjects: 1803
Study: 36592507

Group type: EXPERIMENTAL
Intervention: Ipilimumab (1 mg/kg every 6 weeks for a maximum of two infusions), Nivolumab (6 mg/kg every four weeks), Tocilizumab (8 mg/kg every four weeks), and SBRT (15 Gy on day one of the first cycle)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ipilimumab, Nivolumab, Tocilizumab, and SBRT
Number of subjects: 26
Study: 36592575

Group type: EXPERIMENTAL
Intervention: Enhanced self-regulation condition (ESR)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Self-regulation condition (SR)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 136
Study: 36592649

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for evaluating endometriosis
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Age distribution analysis
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Visual analog scale for pain severity
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Uterine contractions visualization
Number of subjects: 345
Study: 36592688

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 36592818

Group type: EXPERIMENTAL
Intervention: Nurse-led task-shifting and mobile health application (Medtronic® Labs' Empower Health), home BP monitoring
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care plus short text messages on health (enhanced usual care arm)
Number of subjects: 240
Study: 36592878

Group type: EXPERIMENTAL
Intervention: Zalunfiban dose 1 (0.110 mg/kg)
Number of subjects: 2499

Group type: EXPERIMENTAL
Intervention: Zalunfiban dose 2 (0.130 mg/kg)
Number of subjects: 2499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499

Group type: EXPERIMENTAL
Intervention: Zalunfiban (both doses)
Number of subjects: 2499
Study: 36593070

Group type: EXPERIMENTAL
Intervention: Ibrutinib monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibrutinib combined with gemcitabine and nab-paclitaxel
Number of subjects: 0
Study: 36593094

Group type: EXPERIMENTAL
Intervention: High levels of TMAO (highest tertile)
Number of subjects: 2379

Group type: COMPARATOR
Intervention: Baseline TMAO tertiles
Number of subjects: 2379
Study: 36593119

Group type: EXPERIMENTAL
Intervention: 50% nicotine lactate
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 100% nicotine lactate
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 50% nicotine benzoate
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 100% nicotine benzoate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Free-base nicotine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 100% vs 50% nicotine lactate
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 100% vs 50% nicotine benzoate
Number of subjects: 116
Study: 36593127

Group type: EXPERIMENTAL
Intervention: SCP plus LHE-delivered information session
Number of subjects: 72

Group type: COMPARATOR
Intervention: SCP alone
Number of subjects: 72
Study: 36593181

Group type: EXPERIMENTAL
Intervention: Standard psychosocial intervention delivered in a child-friendly space (CFS) for 12 weeks
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Toolkit for Child-Friendly Spaces in Humanitarian Settings for 12 weeks
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1280
Study: 36593652

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (VarV) and inactivated hepatitis A vaccine (HepA) co-administered (Group A)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (Group B) - VarV and HepA administered separately
Number of subjects: 450
Study: 36593702

Group type: EXPERIMENTAL
Intervention: Weekly umbilical artery Doppler ultrasound
Number of subjects: 292

Group type: COMPARATOR
Intervention: Bi-weekly umbilical artery Doppler ultrasound
Number of subjects: 292
Study: 36593729

Group type: EXPERIMENTAL
Intervention: Corticosteroid tapering in patients receiving subcutaneous daratumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous daratumumab
Number of subjects: 0
Study: 36593888

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with Yttrium-90 resin microspheres
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Partition model dosimetry
Number of subjects: 422
Study: 36594077

Group type: EXPERIMENTAL
Intervention: 5 mm-bolus on alternate days (SR group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 5 mm-bolus daily (HR group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No bolus (SR group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 5 mm-bolus on alternate days (HR group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 5-year local control (SR group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 5-year local control (HR group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall radiodermatitis burden
Number of subjects: 58
Study: 36594167

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin in combination with venetoclax and an anti-CD20 antibody
Number of subjects: 50
Study: 36594181

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 36594185

Group type: EXPERIMENTAL
Intervention: Vaccination with Triplex (5.1 × 10^8 pfu)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study: 36594212

Group type: EXPERIMENTAL
Intervention: D-β-hydroxybutyrate
Number of subjects: 0
Study: 36594231

Group type: EXPERIMENTAL
Intervention: WE CARE Houston social needs intervention (screener and resource referrals based on screening results and receptiveness to help)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 413
Study: 36594428

Group type: EXPERIMENTAL
Intervention: Low protein diet (LPD) (0.6 to 0.8 g/kg/day)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Usual or unrestricted protein diet (UPD) (≥ 1.0 g/kg/day)
Number of subjects: 486
Study: 36594430

Group type: EXPERIMENTAL
Intervention: Aripiprazole added to venlafaxine XR
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo added to venlafaxine XR
Number of subjects: 178
Study: 36594748

Group type: EXPERIMENTAL
Intervention: Robot-assisted TME (R-TME)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Laparoscopy-assisted TME (L-TME)
Number of subjects: 295
Study: 36594752

Group type: EXPERIMENTAL
Intervention: Glaucoma question prompt list/video intervention
Number of subjects: 189
Study: 36594814

Group type: EXPERIMENTAL
Intervention: Fibrin glue applied to iatrogenic ulcers after standard ESD
Number of subjects: 247

Group type: COMPARATOR
Intervention: Standard ESD (Control)
Number of subjects: 247
Study: 36594820

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 261

Group type: COMPARATOR
Intervention: Cefotaxime, Ceftriaxone, Ciprofloxacin
Number of subjects: 261